Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $2.2 million.

  • Editas Medicine's Share-based Compensation fell 5360.27% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 4771.35%. This contributed to the annual value of $21.4 million for FY2024, which is 817.76% up from last year.
  • Editas Medicine's Share-based Compensation amounted to $2.2 million in Q3 2025, which was down 5360.27% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Share-based Compensation ranged from a high of $13.5 million in Q2 2021 and a low of $2.2 million during Q3 2025
  • For the 5-year period, Editas Medicine's Share-based Compensation averaged around $6.4 million, with its median value being $5.3 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 14969.54% in 2021, then tumbled by 6072.51% in 2025.
  • Over the past 5 years, Editas Medicine's Share-based Compensation (Quarter) stood at $7.7 million in 2021, then fell by 29.95% to $5.4 million in 2022, then dropped by 0.35% to $5.3 million in 2023, then dropped by 24.79% to $4.0 million in 2024, then crashed by 44.58% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.7 million for Q2 2025, and $3.0 million during Q1 2025.